Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 39

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 39
---
ulation formation; b = Evidence of bone remodeling; c = Absence of radiolucent areas

[Changes in p-value according to the number of subjects]

    Success  
    Fail  
    # of patients  
    p-value  
      
    Success  
    Fail  
    # of patients  
    p-value 
  
    Control 
     2  
     5  
     7  
        
    Control 
     3  
     8  
     11  

    Test 
     6  
     2  
     8  
     0.132  
    Test 
     9  
     3  
     2  
     0.039 

     15  

     23  

    Success  
    Fail  
    # of patients  
    p-value  
      
    Success  
    Fail  
    # of patients  
    p-value 
  
    Control 
     4  
     0  
     4  
        
    Control 
     9  
     9  
     28  

    Test 
     2  
     4  
     6  
     0.026  
    Test 
     24  
     8  
     32  
     0.002 

     30  

     60  

Note: S = Bone Fusion Success; F = Bone Fusion Failure; a = Continuous
trabeculation formation; b = Evidence of bone remodeling; c = Absence of radiolucent areas

22

The clinical trial results indicate that the success rate in the test
group was significantly higher at 75%, compared to only 25% in the control group. Additionally, the failure rate in the control group
was 71.4%, which was markedly higher than the 28.6% observed in the test group. These findings demonstrate that the test group, which
received DRT-102, exhibited a substantially better outcome in terms of bone fusion compared to the control group. Overall, the data strongly
suggest that DRT-102 is more effective than the control treatment in promoting bone fusion.

The chi-square test of the study demonstrates how the p-value changes
with varying sample sizes in the clinical trial, comparing the control and test groups.